Physician profile
Mark J Milone
NPI 1881635803
$1,277.50
in general payments reported to CMS, 2019-2025
12 companies · $319 in 2025
The $319 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.59 · 2020: $159 · 2022: $41.31 · 2023: $161 · 2024: $550 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.66 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $513.28 | 2024-2025 | Tremfya, Stelara |
| Olympus America INC. | $230.62 | 2020-2023 | Endoclot Phs |
| Genzyme Corporation | $153.30 | 2024 | |
| Phathom Pharmaceuticals, INC. | $79.78 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $74.75 | 2023-2024 | Dupixent |
| Abbvie INC. | $74.23 | 2023-2024 | |
| Baxter Healthcare | $47.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.41 | 2023 | Entyvio |
| Pfizer INC. | $19.02 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Braintree Laboratories, INC. | $15.41 | 2024 | Suflave |
| Ferring Pharmaceuticals INC. | $15.00 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Milone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.